Literature DB >> 1357564

Serotonergic pathology is not widespread in Alzheimer patients without prominent aggressive symptoms.

A W Procter1, P T Francis, G C Stratmann, D M Bowen.   

Abstract

Behavioural symptoms of Alzheimer's disease, such as aggression, may determine the care patients required. Most postmortem neurochemical studies have been of institutionalized patients and conclusions drawn from these may not be valid for all patients. We have shown that serotonin 2 receptors are not lost from 12 of the 13 areas of cerebral cortex examined in the patients assessed to be free of aggressive symptoms. This has been interpreted as representing the relative preservation of cortical interneurones. In contrast choline acetyltransferase activity was reduced in all areas whereas serotonin content was reduced in only 2 of the 4 areas examined.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1357564     DOI: 10.1007/bf00993268

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  31 in total

1.  Evidence of glutamatergic denervation and possible abnormal metabolism in Alzheimer's disease.

Authors:  A W Procter; A M Palmer; P T Francis; S L Lowe; D Neary; E Murphy; R Doshi; D M Bowen
Journal:  J Neurochem       Date:  1988-03       Impact factor: 5.372

2.  Troublesome and disruptive behaviors in dementia. Relationships to diagnosis and disease severity.

Authors:  J M Swearer; D A Drachman; B F O'Donnell; A L Mitchell
Journal:  J Am Geriatr Soc       Date:  1988-09       Impact factor: 5.562

3.  Alzheimer's disease.

Authors:  R H Wilkins; I A Brody
Journal:  Arch Neurol       Date:  1969-07

4.  5 HT2 receptors in dementia of Alzheimer type: a quantitative autoradiographic study of frontal cortex and hippocampus.

Authors:  D Dewar; D I Graham; J McCulloch
Journal:  J Neural Transm Park Dis Dement Sect       Date:  1990

5.  5-Hydroxytryptamine1A but not 5-hydroxytryptamine2 receptors are enriched on neocortical pyramidal neurones destroyed by intrastriatal volkensin.

Authors:  P T Francis; M N Pangalos; R C Pearson; D N Middlemiss; G C Stratmann; D M Bowen
Journal:  J Pharmacol Exp Ther       Date:  1992-06       Impact factor: 4.030

6.  Preliminary report on affective symptoms in the early stages of senile dementia of the Alzheimer type.

Authors:  J W Knesevich; R L Martin; L Berg; W Danziger
Journal:  Am J Psychiatry       Date:  1983-02       Impact factor: 18.112

7.  Cortical serotonin-S2 receptor binding abnormalities in patients with Alzheimer's disease: comparisons with Parkinson's disease.

Authors:  E K Perry; R H Perry; J M Candy; A F Fairbairn; G Blessed; D J Dick; B E Tomlinson
Journal:  Neurosci Lett       Date:  1984-10-26       Impact factor: 3.046

8.  Gamma-aminobutyric acid concentration in brain tissue at two stages of Alzheimer's disease.

Authors:  S L Lowe; P T Francis; A W Procter; A M Palmer; A N Davison; D M Bowen
Journal:  Brain       Date:  1988-08       Impact factor: 13.501

9.  Behavioral correlates of computed tomographic (CT) scan changes in older psychiatric patients.

Authors:  M E Swigar; F M Benes; S L Rothman; C Opsahl; M M Dowds
Journal:  J Am Geriatr Soc       Date:  1985-02       Impact factor: 5.562

10.  Presynaptic serotonergic dysfunction in patients with Alzheimer's disease.

Authors:  A M Palmer; P T Francis; J S Benton; N R Sims; D M Mann; D Neary; J S Snowden; D M Bowen
Journal:  J Neurochem       Date:  1987-01       Impact factor: 5.372

View more
  10 in total

1.  Citalopram for agitation in Alzheimer's disease: design and methods.

Authors:  Lea T Drye; Zahinoor Ismail; Anton P Porsteinsson; Paul B Rosenberg; Daniel Weintraub; Christopher Marano; Gregory Pelton; Constantine Frangakis; Peter V Rabins; Cynthia A Munro; Curtis L Meinert; D P Devanand; Jerome Yesavage; Jacobo E Mintzer; Lon S Schneider; Bruce G Pollock; Constantine G Lyketsos
Journal:  Alzheimers Dement       Date:  2012-02-01       Impact factor: 21.566

Review 2.  Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer's Disease.

Authors:  Celina S Liu; Sarah A Chau; Myuri Ruthirakuhan; Krista L Lanctôt; Nathan Herrmann
Journal:  CNS Drugs       Date:  2015-08       Impact factor: 5.749

3.  Loss of serotonin 5-HT2A receptors in the postmortem temporal cortex correlates with rate of cognitive decline in Alzheimer's disease.

Authors:  M K Lai; S W Tsang; J T Alder; J Keene; T Hope; M M Esiri; P T Francis; C P Chen
Journal:  Psychopharmacology (Berl)       Date:  2004-11-18       Impact factor: 4.530

4.  Somatostatin-like immunoreactivity, its molecular forms and monoaminergic metabolites in aged and demented patients with Parkinson's disease--effect of L-Dopa.

Authors:  M Strittmatter; G F Hamann; D Strubel; H Cramer; K Schimrigk
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

5.  Disruptive behavior as a predictor in Alzheimer disease.

Authors:  Nikolaos Scarmeas; Jason Brandt; Deborah Blacker; Marilyn Albert; Georgios Hadjigeorgiou; Bruno Dubois; Davangere Devanand; Lawrence Honig; Yaakov Stern
Journal:  Arch Neurol       Date:  2007-12

6.  Imbalance of a serotonergic system in frontotemporal dementia: implication for pharmacotherapy.

Authors:  D M Bowen; A W Procter; D M A Mann; J S Snowden; M M Esiri; D Neary; P T Francis
Journal:  Psychopharmacology (Berl)       Date:  2007-11-18       Impact factor: 4.530

7.  Brain aging research at the close of the 20th century: from bench to bedside.

Authors:  C Cidis Meltzer; P T Francis
Journal:  Dialogues Clin Neurosci       Date:  2001-09       Impact factor: 5.986

8.  Potential cognitive enhancing and disease modification effects of SSRIs for Alzheimer's disease.

Authors:  Tiffany W Chow; Bruce G Pollock; Norton W Milgram
Journal:  Neuropsychiatr Dis Treat       Date:  2007       Impact factor: 2.570

9.  Serotonin 5-HT2A and 5-HT6 receptors in the prefrontal cortex of Alzheimer and normal aging patients.

Authors:  Dietrich E Lorke; Gang Lu; Eric Cho; David T Yew
Journal:  BMC Neurosci       Date:  2006-04-27       Impact factor: 3.288

10.  Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial.

Authors:  Stephan Ehrhardt; Anton P Porsteinsson; Cynthia A Munro; Paul B Rosenberg; Bruce G Pollock; Davangere P Devanand; Jacobo Mintzer; Tarek K Rajji; Zahinoor Ismail; Lon S Schneider; Sheriza N Baksh; Lea T Drye; Dimitri Avramopoulos; David M Shade; Constantine G Lyketsos
Journal:  Alzheimers Dement       Date:  2019-10-03       Impact factor: 16.655

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.